entertainment -WSS

entertainment

author：entertainment 2025-09-02 22:07:25 - browse：355

Emma Walmsley on stage at the 2023 STAT Summit. — GSK CEO Emma Walmsley at the 2023 STAT Summit. STAT

The story of GSK is one of reinvention, CEO Emma Walmsley said at the STAT Summit in Boston on Thursday. Having shed its consumer division, the British drug giant is writing a new chapter as a pure-play biopharma company dedicated to the prevention, as well as treatment, of disease.

GSK’s recent launch of a new RSV vaccine for adults is emblematic of this move, adding to a portfolio that includes other vaccines, such as the very successful Shingrix for shingles, as well as drugs for HIV, other infectious diseases, and cancer, among others. But what does the growing sentiment against vaccination, not just in the United States but around the world, mean for such a bet on this market?

“It’s a very, very serious issue,” Walmsley said, noting that in 11 U.S. states, basic vaccination rates are now lower than they were before Covid. “The answer can’t be sort of flinging science over the airwaves and saying ‘trust us,’ because people don’t. There is a really serious challenge of misinformation and the ongoing issue of politicization, which I suspect is going to get more challenging in the next year for obvious reasons.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： There's an unseen cost to disruptive road

focus

knowledge

WSS

TikTok, Instagram influencers need more rules for drug ads

Amazon on where the company's health care bets are headed next

There's an unseen cost to disruptive road

Why Novartis is changing the name of its research labs

Advances in CAR

The inclusion problem at the heart of rehabilitation research

entertainment

entertainment

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Immunocompromised patients offer clues on chronic Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Maisha Meds is a PBM, but don't call it that

Medicare details structure of new drug price negotiation program

The inclusion problem at the heart of rehabilitation research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Dana Farber says 6 studies to be retracted and 31 corrected

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

There's an unseen cost to disruptive road

explore

Mass General, Mayo Clinic look to monetize custom

What drug price negotiations mean for Medicare Part D

Future doctors need a strong humanities education

HPV vaccine, cervical cancer study delivers historic results

Humana sues Biden admin over Medicare Advantage audit rule

To bolster infectious disease surveillance, genomics powerhouses team up

focus

knowledge

hotspot

entertainment